Greetings, this is Daily Stock, bringing you selected core information on domestic and global financial markets.
[Image: /stdaily/uploads/202606/gen_6a252545893522.88664060.png]
Core Summary
Alteogen (196170), one of Kosdaq's leading large-cap stocks, is entering a full-scale milestone (step-by-step licensing fees) inflow phase based on its proprietary subcutaneous (SC) formulation platform technology.
With Keytruda SC's US and global sales starting in earnest this year alongside new licensing agreements, cash inflows worth hundreds of billions of won are highly anticipated.
Specifically, 2026 is expected to be the inaugural year where large-scale royalties and milestones materialize into actual corporate earnings, moving beyond mere market expectations.
Recent rulings by the US Patent Trial and Appeal Board (PTAB) have also significantly alleviated previously raised patent risks.
Market Conditions Update
The Kosdaq index currently hovers around the 1,002.44 level, maintaining a volatile path led by growth stocks.
With the USD/KRW exchange rate reaching 1,559.70 won, the high-exchange-rate environment acts as a favorable macroeconomic tailwind for Alteogen, which secures its technology export contracts based in US dollars.
According to Daily Stock's proprietary Fear & Greed Index, the Kospi—closely tied to Kosdaq—remains in the Neutral (51.8) stage.
The Nasdaq Fear & Greed Index is also at a Neutral (42.1) level, reflecting a cautious wait-and-see market stance. Amid this climate, Alteogen is striving to carve out differentiated momentum based on individual positive catalysts.
On June 5, Alteogen published a shareholder notice detailing its global partnership progress and milestone outlook.
The company projected that it could receive milestone payments exceeding 300 billion won from Merck (MSD) this year, driven by expanding Keytruda SC sales.
Furthermore, following contracts signed earlier this year with Biogen and GSK's subsidiary Tesaro, the company revealed that it is currently negotiating final contracts with approximately 10 global big pharma players under Material Transfer Agreements (MTAs), driving up expectations for additional technology exports.
Financial Analysis
Alteogen posted record-high performance for the consolidated fiscal year 2025, recording revenue of 215.9 billion won and an operating profit of 106.9 billion won.
This represents an explosive year-over-year surge of 110% in revenue and 321% in operating profit, reflecting the commercial success of its platform technology.
Its recently disclosed preliminary Q1 2026 results showed 71.6 billion won in revenue and 39.3 billion won in operating profit.
While this is a slight drop compared to the same period last year due to high base effects from a previous massive technology licensing deal, the operating profit margin remained robust at a high 54.9%, proving strong fundamental quality.
[Table 1: Alteogen Annual Performance Trend and Forecast]
| Category | FY2024 (Confirmed) | FY2025 (Confirmed) | FY2026 (Securities Firms Forecast) |
|---|---|---|---|
| Revenue | 102.8 billion KRW | 215.9 billion KRW | 454.0 billion KRW |
| Operating Profit | 25.4 billion KRW | 106.9 billion KRW | 295.0 billion KRW |
| Operating Margin | 24.7% | 49.5% | 64.9% |
| Net Income | 60.6 billion KRW | 144.3 billion KRW | Approx. over 250.0 billion KRW |
* The FY2026 projections are reconstructed based on market consensus from major securities firms, including Daishin Securities.
[Image: /stdaily/uploads/202606/gen_6a25255183fc75.28642135.png]
Valuation
Alteogen’s share price was not updated on Sunday, June 7, 2026, due to the weekend market closure; the stock closed at 332,500 won on the previous trading day, June 5.
While trading at a high Price-to-Earnings (P/E) ratio, this is interpreted as the market pre-reflecting the long-term sustainable cash-flow value of its platform technology.
Though valued at levels difficult to justify through traditional valuation metrics, quarterly earnings per share (EPS) are projected to improve rapidly as milestones flow in.
Specifically, with prescriptions surging after Keytruda SC's J-Code went into effect in the US, scenarios suggesting a gradual easing of valuation burdens once royalty-based cash flows stabilize are gaining traction.
Professional & Institutional Analysis
Financial investment industry experts, including those at Daishin Securities, maintain a positive outlook, setting target prices for Alteogen around the 500,000 won range.
Analysts forecast that Keytruda SC sales milestones will sequentially expand to approximately 300 billion won this year and 400 billion won next year.
Furthermore, having secured platform patent protection until 2043, the visibility of its long-term cash flows is considered exceptionally high.
Furthermore, analysts point out that if the platform's scalability is validated in ADC (antibody-drug conjugates) such as Enhertu SC and bispecific antibodies, additional market re-rating is highly plausible.
Risk Factors
The most notable risk is profit-taking pressure across growth stocks due to changes in global interest rate environments and market liquidity.
If the biotech sector suffers from investor neglect amid prolonged high-interest rates, share price volatility could widen regardless of individual corporate catalysts.
In addition, a time lag exists before multiple MTA agreements convert into final execution contracts, and the possibility of final deals falling through for certain option agreements cannot be ruled out.
The development speed of subcutaneous technologies by global competitors and potential clinical delays by partners also remain key variables to monitor closely.
Investment Perspective Summary
Alteogen is not a firm relying merely on drug development hype; it has successfully established a business model that secures royalties from global pharmaceutical giants through validated platform technology.
Rather than being swayed by short-term supply-demand fluctuations or temporary quarterly revenue dips, focusing on its medium- to long-term milestone inflow pipelines and pipeline expansions seems to be an effective strategy.
However, due to the nature of licensing-out companies, share prices can exhibit high volatility aligned with disclosure schedules. A cautious approach through split-buying is recommended.
It is critical to observe how Alteogen solidifies its independent fundamentals amid macroeconomic uncertainties and foreign exchange market volatility.
Investor Checklist Q&A
Q1. Is the recently announced 300 billion won milestone inflow projection for Alteogen reliable?
A1. According to foreign media including Bloomberg, Keytruda SC's global sales are projected to reach approximately $2 billion this year. With sales accelerating due to the US J-Code enactment, the projection is deemed highly feasible.
Q2. What major licensing agreements were newly signed earlier this year?
A2. In January, Alteogen signed a deal with GSK's subsidiary Tesaro to develop a subcutaneous formulation for Jemperli (worth up to 420.0 billion won). In March, it closed a large-scale agreement with Biogen to develop SC formulations for two therapeutic products.
Q3. How have the patent disputes and risks with Halozyme been resolved?
A3. The US Patent Trial and Appeal Board (PTAB) ruled to invalidate competitor Halozyme’s core patents, and Halozyme's petition to invalidate Alteogen's process patents was dismissed, significantly reducing patent-related risks.
Q4. What caused the slight drop in Q1 2026 results, and is it a cause for concern?
A4. It is a temporary phenomenon caused by a high base effect, such as the upfront payment inflow from the AstraZeneca contract last year. The general consensus among experts is that this does not represent damaged fundamentals, given the high 54.9% operating profit margin in Q1.
Q5. How many Material Transfer Agreement (MTA) partners are currently in discussions for additional contracts?
A5. Even after executing final contracts with some firms earlier this year, new preliminary partners have entered negotiations. Alteogen is reportedly discussing final contract terms with around 10 global big pharma companies.